Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,559,002
  • Shares Outstanding, K 94,867
  • Annual Sales, $ 1,046 M
  • Annual Income, $ 407,300 K
  • 60-Month Beta 0.74
  • Price/Sales 7.31
  • Price/Cash Flow 17.12
  • Price/Book 5.62
Trade NBIX with:

Options Overview Details

View History
  • Implied Volatility 48.26%
  • Historical Volatility 21.94%
  • IV Percentile 80%
  • IV Rank 59.73%
  • IV High 59.30% on 03/09/21
  • IV Low 31.88% on 05/26/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 91
  • Volume Avg (30-Day) 459
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 1,217
  • Open Int (30-Day) 3,294

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 0.59
  • Number of Estimates 8
  • High Estimate 0.90
  • Low Estimate 0.26
  • Prior Year 3.58
  • Growth Rate Est. (year over year) -83.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.31 +3.04%
on 12/06/21
93.93 -14.10%
on 11/08/21
-12.52 (-13.43%)
since 11/05/21
3-Month
78.31 +3.04%
on 12/06/21
108.01 -25.30%
on 11/01/21
-15.18 (-15.83%)
since 09/03/21
52-Week
78.31 +3.04%
on 12/06/21
120.27 -32.91%
on 01/25/21
-15.84 (-16.41%)
since 12/04/20

Most Recent Stories

More News
Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance

Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

MRK : 73.42 (+0.11%)
NBIX : 80.69 (+1.27%)
ESPR : 5.61 (+6.86%)
XNCR : 34.53 (-1.79%)
Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NBIX : 80.69 (+1.27%)
Neurocrine: Q3 Earnings Snapshot

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported third-quarter net income of $22.5 million, after reporting a loss in the same period a year earlier.

NBIX : 80.69 (+1.27%)
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NBIX : 80.69 (+1.27%)
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its movement disorder treatments for...

NBIX : 80.69 (+1.27%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter 2021 financial results after the Nasdaq market...

NBIX : 80.69 (+1.27%)
Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a collaboration with renowned contemporary artist, Jorge Rodriguez-Gerada best...

NBIX : 80.69 (+1.27%)
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone

Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021

XENE : 24.73 (-0.12%)
NBIX : 80.69 (+1.27%)
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027

Palm Beach, FL – May 5, 2021 – Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain...

GWHP : 0.1346 (-6.14%)
ADMS : 8.22 (+0.74%)
BLRX : 2.14 (-3.60%)
AXSM : 32.91 (+2.08%)
NBIX : 80.69 (+1.27%)
Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have entered into a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed...

NBIX : 80.69 (+1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 85.23
2nd Resistance Point 83.37
1st Resistance Point 82.03
Last Price 80.69
1st Support Level 78.83
2nd Support Level 76.97
3rd Support Level 75.63

See More

52-Week High 120.27
Fibonacci 61.8% 104.24
Fibonacci 50% 99.29
Fibonacci 38.2% 94.34
Last Price 80.69
52-Week Low 78.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar